Steven Macina, DO
Psychiatry · Huntington Beach, CANPI 1124130471
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.
Across 37 payments — averaging $46.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$363
- Teva Pharmaceuticals USA, Inc.$237
- E.r. Squibb & Sons, L.L.C.$231
- Neurocrine Biosciences, Inc.$203
- Otsuka America Pharmaceutical, Inc.$169
- AbbVie$150
- plus $358 from 6 others
Across 1,550 payments — averaging $7157.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$4.9M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3.3M
- Sumitomo Pharma America, Inc.$547K
- E.r. Squibb & Sons, L.L.C.$475K
- Sunovion Pharmaceuticals Inc.$383K
- AbbVie$381K
- plus $1.1M from 11 others
What the payments were for
- Food & beverage$1,65997%
- Education$533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 3 | $363 |
| Teva Pharmaceuticals USA, Inc. | 6 | $237 |
| E.r. Squibb & Sons, L.L.C. | 8 | $231 |
| Neurocrine Biosciences, Inc. | 5 | $203 |
| Otsuka America Pharmaceutical, Inc. | 4 | $169 |
| AbbVie | 2 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $146 |
| Eisai Inc. | 1 | $120 |
| Indivior Inc. | 3 | $49 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,712 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 254 | $672,108 |
| Aripiprazole OdtAripiprazole | 162 | $216,059 |
| FanaptIloperidone | 72 | $194,234 |
| VraylarCariprazine Hcl | 116 | $159,818 |
| RexultiBrexpiprazole | 62 | $99,185 |
| Risperidone OdtRisperidone | 366 | $97,398 |
| Risperdal ConstaRisperidone Microspheres | 47 | $86,614 |
| TrintellixVortioxetine Hydrobromide | 86 | $54,240 |
| Olanzapine OdtOlanzapine | 376 | $49,542 |
| Clozapine | 600 | $45,776 |
| AristadaAripiprazole Lauroxil | 11 | $35,755 |
| Clozapine OdtClozapine | 64 | $30,443 |
| Lurasidone Hcl | 134 | $26,652 |
| Lamotrigine OdtLamotrigine | 36 | $21,998 |
| Divalproex Sodium ErDivalproex Sodium | 327 | $20,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $14 | $758,722301 claims |
| AbbVieVraylar | $150 | $159,818116 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $169 | $99,18562 claims |
| Alkermes, Inc.Aristada | $363 | $35,75511 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $237 | $3,54952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Huntington Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.